Literature DB >> 17469153

Predictors of mortality in adults with cystic fibrosis.

J M Courtney1, J Bradley, J Mccaughan, T M O'Connor, C Shortt, C P Bredin, I Bradbury, J S Elborn.   

Abstract

Assessment of prognostic indicators in patients with cystic fibrosis (CF) is important. The study's aim was to assess the relative contribution of gender, genetics and microbiology on survival in adults with CF. Adult patients were studied from 1995 to 2005 and data collected included FEV(1) (%predicted), body mass index (BMI), genetics, and microbiology. Data was available on 183 patients in 1995. Forty-five patients died in the subsequent 10 years. Patients who died during the study had lower mean (SD) FEV(1) %predicted in 1995 when compared to those remaining alive, 41.5 (15.2)% versus 69.8 (23.2)% predicted, respectively, P<0.001 and they had lower mean (SD) BMI in 1995, 19.2 (3.3) kg/m(2) in comparison to those remaining alive, 20.7 (3.4) kg/m(2), P=0.008. The proportion of patients infected with Pseudomonas aeruginosa and Burkholderia cepacia complex was higher in the group who died during the study compared to those remaining alive, odds ratio 20.9 P<0.0001 and 7.1 P<0.0001, respectively. The presence of the Delta F508 homozygous mutation did not alter survival, P=0.3. Patients infected with either P.aeruginosa or B.cepacia complex had reduced survival compared to those without infection, P=0.01 and P<0.0001, respectively. FEV(1)% (P<0.0001), infection with P.aeruginosa (P=0.005) or B.cepacia complex (P=0.03) were the only significant predictors of mortality. This study demonstrates adults who died were more likely to have worse lung function and be infected with either P.aeruginosa or B.cepacia complex. FEV(1)% and infection with P.aeruginosa or B.cepacia complex were the most significant predictors of survival in adults with CF. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17469153     DOI: 10.1002/ppul.20619

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  54 in total

1.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

2.  Volatile fingerprinting of Pseudomonas aeruginosa and respiratory syncytial virus infection in an in vitro cystic fibrosis co-infection model.

Authors:  Giorgia Purcaro; Christiaan A Rees; Jeffrey A Melvin; Jennifer M Bomberger; Jane E Hill
Journal:  J Breath Res       Date:  2018-07-03       Impact factor: 3.262

3.  A Screen for Antibiotic Resistance Determinants Reveals a Fitness Cost of the Flagellum in Pseudomonas aeruginosa.

Authors:  E A Rundell; N Commodore; A L Goodman; B I Kazmierczak
Journal:  J Bacteriol       Date:  2020-02-25       Impact factor: 3.490

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis.

Authors:  Don B Sanders; Zhanhai Li; Alan S Brody; Philip M Farrell
Journal:  Am J Respir Crit Care Med       Date:  2011-10-01       Impact factor: 21.405

6.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

7.  Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with cystic fibrosis.

Authors:  Helen R Hickey; Ashley P Jones; Warren Lenney; Paula R Williamson; Rosalind L Smyth
Journal:  Trials       Date:  2010-02-05       Impact factor: 2.279

8.  Rehabilitation Programs for Cystic Fibrosis - View from a CF Center.

Authors:  M Griese; P Busch; D Caroli; B Mertens; C Eismann; M Harari; H Staudter; M Kappler
Journal:  Open Respir Med J       Date:  2010-01-07

Review 9.  Metabolism and function of phenazines in bacteria: impacts on the behavior of bacteria in the environment and biotechnological processes.

Authors:  Leland S Pierson; Elizabeth A Pierson
Journal:  Appl Microbiol Biotechnol       Date:  2010-03-30       Impact factor: 4.813

10.  Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain.

Authors:  Shihab Hameed; John R Morton; Adam Jaffé; Penny I Field; Yvonne Belessis; Terence Yoong; Tamarah Katz; Charles F Verge
Journal:  Diabetes Care       Date:  2009-11-12       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.